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Abstract: 
Recently, the pyrazole-containing synthetic cannabinoid (SC) N-(1-amino-
3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-
pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) has been identified as a 
‘research chemical’ both in powdered form and as an adulterant present in 
herbal preparations. Urine is the most common matrix used for abstinence 
control and the extensive metabolism of SCs requires implementation of 
targeted analysis. The present study describes the investigation of the in 
vitro phase I metabolism of 3,5-AB-CHMFUPPYCA and its regioisomer 5,3-
AB-CHMFUPPYCA using pooled human liver microsomes. Metabolic patterns 
of both AB-CHMFUPPYCA isomers were qualitatively similar and dominated 
by oxidation of the cyclohexylmethyl side chain. Biotransformation to 
monohydroxylated metabolites of high abundance confirmed that these 
species might serve as suitable targets for urine analysis. Furthermore, 
since SCs are commonly administered by smoking and because some 
metabolites can also be formed as thermolytic artefacts, the stability of 
both isomers was assessed under smoking conditions. Under these 
conditions, pyrolytic cleavage of the amide bond occurred that led to 
approximately 3 % conversion to heat-induced degradation products that 
were also detected during metabolism. These artefactual ‘metabolites’ 
could potentially bias in vivo metabolic profiles after smoking and might 
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have to be considered for interpretation of metabolite findings during hair 
analysis. This might be relevant in the analysis of hair samples where 
detection of metabolites is generally accepted as a strong indication of 
drug use rather than a potential external contamination. 
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Abstract 
 
Recently, the pyrazole-containing synthetic cannabinoid (SC) N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide 
(3,5-AB-CHMFUPPYCA) has been identified as a ‘research chemical’ both in powdered 
form and as an adulterant present in herbal preparations. Urine is the most common matrix 
used for abstinence control and the extensive metabolism of SCs requires implementation of 
targeted analysis. The present study describes the investigation of the in vitro phase I 
metabolism of 3,5-AB-CHMFUPPYCA and its regioisomer 5,3-AB-CHMFUPPYCA using 
pooled human liver microsomes. Metabolic patterns of both AB-CHMFUPPYCA isomers 
were qualitatively similar and dominated by oxidation of the cyclohexylmethyl side chain. 
Biotransformation to monohydroxylated metabolites of high abundance confirmed that these 
species might serve as suitable targets for urine analysis. Furthermore, since SCs are 
commonly administered by smoking and because some metabolites can also be formed as 
thermolytic artefacts, the stability of both isomers was assessed under smoking conditions. 
Under these conditions, pyrolytic cleavage of the amide bond occurred that led to 
approximately 3 % conversion to heat-induced degradation products that were also detected 
during metabolism. These artefactual ‘metabolites’ could potentially bias in vivo metabolic 
profiles after smoking and might have to be considered for interpretation of metabolite 
findings during hair analysis. This might be relevant in the analysis of hair samples where 
detection of metabolites is generally accepted as a strong indication of drug use rather than a 
potential external contamination. 
 
Keywords: LC-MS/MS; metabolism; new psychoactive substances; pooled human liver 
microsomes; synthetic cannabinoids  
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Introduction 
 
Cannabinoid receptor agonists, commonly referred to as synthetic cannabinoids, are the 
predominant class within the group of new psychoactive substances (NPS) with over 150 
distinct structures reported via the European Early Warning System (EWS) to the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDAA) until October 2015[1]. Over the 
last seven years, the synthetic cannabinoids offered for purchase have undergone significant 
structural changes. While in the beginning mostly N-alkyl substituted naphthoylindoles were 
sold (e.g. JWH-018, JWH-210 and AM-2201), the majority of the synthetic cannabinoids 
offered in 2015 contain either indole or indazole core structures along with valinamide, 
methyl-valinamide or methyl ester variants of these structures (e.g. MDMB-CHMICA, AB-
FUBINACA, AB-CHMINACA). Recently, three different synthetic cannabinoids comprising 
a pyrazole core structure were identified on the ‘legal high’ market (Figure 1). Girreser et al. 
reported the identification of the designer drug 3,5-5F-ADB-FUPPYCA (N-(1-amino-3,3-
dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide)[2] 
and McLaughlin et al. identified 3,5-AB-CHMFUPPYCA (N-(1-amino-3-methyl-1-oxobutan-
2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxamide) in a powder 
falsely classified as AZ-037 (5F-AB-FUPPYCA[3], N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
(5-fluoropentyl)-5-(4-fluorophenyl)-1H-pyrazole-3-carboxamide), a compound which was 
itself reported through the EWS in June 2015[1]. Uchiyama et al. also detected 
3,5-AB-CHMFUPPYCA in an ‘herbal mixture’ sold in Japan and referred to it, following a 
semi-systematic nomenclature naming approach, as AB-CHFUPYCA[4]. Apart from the three 
pyrazole compounds identified on the drug market, the synthesis of the 5,3-regioisomer of 
3,5-AB-CHMFUPPYCA was also described in the literature[3]. No pharmacological data 
regarding these novel compounds is available so far. As many pyrazole compounds like 
rimonabant (SR141716A) bind to the CB1 receptor as an antagonist, while some pyrrole 
compounds like JWH-307 show agonist properties with a high CB1 binding affinity[5], 
collection of such data would be of high interest. Even without this data, the appearance of 
these compounds on the ‘legal high’ market render it likely that these compounds may be 
capable of producing cannabis-like effects and show potential for misuse. 
Offering a non-invasive sample collection with a relatively wide window of detection, urine 
analysis is usually the method of choice for abstinence control. In the case of synthetic 
cannabinoids, the parent compounds are rarely excreted unchanged in urine and in most cases, 
after cleavage with glucuronidase, the phase I main metabolites are suitable target analytes[6-
9]. Consequently, the metabolism of a new synthetic cannabinoid needs to be known prior to 
updating analytical methods. In cases where no authentic human sample material with 
confirmed uptake of the particular compound is available, pooled human liver microsomes 
(pHLM) offer an inexpensive and fast alternative to gain preliminary data on phase I 
metabolites to be expected. Furthermore, the pHLM extracts can be used for LC-MS/MS 
method development. 
The present study describes the investigation of the in vitro phase I metabolites of 
3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA using pHLM. Since synthetic 
cannabinoids are commonly administered by smoking, the thermolytic stability of both 
isomers was also assessed under smoking conditions as some of the metabolites of synthetic 
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cannabinoids can also be formed as artefacts[10], which can be of particular importance in 
terms of hair analysis. 
 
Experimental 
 
Chemicals and reagents 
 
Formic acid (Rotipuran® ≥ 98 %, p.a.), potassium hydrogen phosphate (≥ 99 %, p.a.) and 
2-propanol (Rotisolv® ≥ 99,95 %, LC-MS grade) were obtained from Carl Roth (Karlsruhe, 
Germany), acetone, acetonitrile (ACN) (LC-MS grade), ammonium formate 10 M 
(99,995 %), potassium hydroxide (puriss. p.a. ≥ 86 % (T) pellets) and superoxide dismutase 
(from bovine erythrocytes) from Sigma-Aldrich (Steinheim, Germany), and methanol from 
VWR (Darmstadt, Germany). Pooled human liver microsomes (pHLM) (50 Donors), 
NADPH-regenerating solutions A/B and 0.5 M potassium phosphate buffer pH 7.4 were 
purchased form Corning (New York, USA). 3,5-AB-CHMFUPPYCA and 
5,3-AB-CHMFUPPYCA were synthesized as described elsewhere[3]. Damiana leaves 
(Turnera diffusa Willd. ex Schult) were purchased from an online vendor (Krautrausch, 
Berlin, Germany). Deionized water was prepared using a cartridge deionizer from Memtech 
(Moorenweis, Germany). For LC-MS/MS analysis mobile phase A consisted of 1 % ACN, 
0.1 % HCOOH, and 2 mM NH4+HCOO- in water, while mobile phase B consisted of ACN 
with 0.1 % HCOOH, and 2 mM NH4+HCOO-. 
 
Identification of the in vitro metabolites (pHLM-Assay) 
To investigate the phase I metabolism of 3,5-AB-CHMFUPPYCA and 5,3-
AB-CHMFUPPYCA, in vitro experiments with pooled human liver microsomes (pHLM) 
were performed in triplicates. Each compound solution (0.5 µL, 1 mg/mL) was added to 
49.5 µL of the pHLM (1 mg/mL) reaction mixture consisting of water, potassium phosphate 
buffer, superoxide dismutase, NADPH-regenerating solutions A/B and pHLM prior to 
incubation for 60 min at 37 °C. The reaction was terminated by the addition of ice-cold 
acetonitrile and the supernatant was analyzed after centrifugation and 1:10 dilution. Blank 
pHLM samples, used as negative controls were processed in the same way. The dilutions of 
the pHLM extracts were screened for potential metabolites applying LC-MS/MS precursor 
ion (Prec) scan, enhanced product ion (EPI) scan, and multiple reaction monitoring (MRM) 
experiments. For precursor ion scan experiments the characteristic fragment ion m/z 189 of 
3,5-AB-CHMFUPPYCA and its 5,3 isomer (Supplemental Figure S1) was used to screen for 
metabolites. In case of the EPI scan experiments, all detected precursor masses and other 
predicted m/z values of potential phase I metabolites comprising mono-, di- and 
trihydroxylation, demethylation, dehalogenation, methylation, carboxylation, amide cleavage, 
dehydrogenation, dealkylation, dihydrodiol formation and ketone formation were included as 
well as combinations of the potential metabolic modifications. Specific mass transitions of the 
identified metabolite showing the most abundant signals were included in a MRM method 
used for abstinence control in urine samples (Supplemental Tables S1 and S2). 
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LC-MS/MS analysis 
The LC-MS/MS system consisted of an Nexera X2 UHPLC (Shimadzu, Duisburg, Germany) 
coupled to a QTRAPTM 5500 triple quadrupole linear ion trap instrument (SCIEX, Darmstadt, 
Germany). Chromatographic separation was performed on a Kinetex® C18 column (2.6 µm, 
100 Å, 100×2.1 mm; Phenomenex, Aschaffenburg, Germany) applying gradient elution as 
follows: starting concentration of mobile phase B was 10 % held for 0.3 min, increased to 
20 % at 0.5 min, further increased to 55 % at 20.0 min, further increased to 95 % at 20.1 min, 
held until 21.9 min, decreased to starting conditions of 10 % at 22.0 min and held 3.0 min for 
equilibration. The flow rate was set to 0.3 mL/min and the autosampler as well as the column 
oven temperatures were set to 10 and 40 °C, respectively. Declustering potentials, entrance 
potentials, collision energies and cell exit potentials were optimized for the two parent 
compounds (Supplemental Table S1 and S2). Ion source temperature and ion source voltage 
were set at 600 °C and +5500 V, respectively. Curtain gas (N2) pressure was 35 psi, ion 
source gas 1 and 2 (compressed air) pressure were 50 and 60 psi and collision gas (N2) 
pressure was set to ‘high’. 
 
Smoke condensate 
To investigate the pyrolytic stability of 3,5-AB-CHMFUPPYCA and its 5,3-isomer during 
smoking, three different joints were prepared. One joint consisted solely of 300 mg dried 
damiana plant material and served as a blank control. The other two joints were prepared with 
300 mg damiana which was sprayed with one milliliter of an acetone solution of 3.5 mg/mL 
3,5-AB-CHMFUPPYCA or 5,3-AB-CHMFUPPYCA, respectively. After air drying 
overnight, the fortified plant material was rolled in a joint. The joints were burned down in 
about 2 min using a water jet pump while the smoke was directed through a wash bottle filled 
with 100 mL methanol. A 0.5 mL aliquot of each smoke condensate solution was evaporated 
to dryness under a gentle stream of nitrogen at 40 °C and reconstituted in 0.5 mL ethyl acetate 
prior to analysis with a GC-MS screening method described elsewhere[11]. Another aliquot 
was reconstituted in mobile phase A/B (50/50, Vol.-%) for LC-MS/MS analysis. 
 
Results and discussion 
 
Identification of the main metabolites 
 
In total, 22 metabolites of 3,5-AB-CHMFUPPYCA, the isomer offered via the Internet and 
found in a ‘herbal mixture’ in Japan, could be detected in the pHLM assay (Table 1). The four 
most abundant metabolites were all products of monohydroxylation at the cyclohexylmethyl 
moiety (A08, A09, A10 and A11). The EPI spectra of these metabolites are shown in 
Figure 2. 
In case of the regioisomer 5,3-AB-CHMFUPPYCA, 23 metabolites were identified in the 
pHLM assay (Table 2). Similar to the 3,5-isomer, the preferred site of oxidative 
biotransformation was the cyclohexylmethyl moiety, leading to three hydroxylation products 
(B06, B13 and B08) and one ketone (B12) as the most abundant metabolites. The EPI spectra 
of these four metabolites are shown in Figure 3. The ranking is solely based on the area ratios 
(metabolite/most abundant metabolite) and does not necessarily reflect actual concentrations. 
This is mainly due to the fact that differences in ionization efficiencies may significantly bias 
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abundance while matrix effects seem to be negligible in pHLM assays with synthetic 
cannabinoids (own unpublished data). 
When comparing the metabolite profiles of the two isomers, 5,3-AB-CHMFUPPYCA 
appeared to be more efficiently metabolized enzymatically under the chosen conditions. 
Supplemental Figure S2 shows exemplary chromatograms for both compounds with a higher 
signal for the unchanged 3,5-AB-CHMFUPPYCA. The metabolites of the two isomers can be 
differentiated by monitoring the transition to m/z 260 as this fragment seemed to be unique to 
the 3,5-substituted compounds. Differentiation might be of interest because the two isomers 
could show different pharmacological activity and could differ with regard to their legal 
status. 
 
In vitro findings do not necessarily correlate with in vivo findings, particularly in terms of the 
ranking regarding relative abundance. Moreover, differences in the relative abundance of 
metabolites might be expected depending on individual phenotype, dose and time of last 
intake. However, taking into account the available data regarding human metabolic 
transformation of chemically related compounds, it is very likely that hydroxylation at the 
cyclohexylmethyl moiety will be among the main metabolic reactions. 
 
Thermolytic stability under smoking conditions 
 
Analysis of the pHLM extracts highlighted the elimination of the cyclohexylmethyl moiety 
for the 3,5-AB-CHMFUPPYCA isomer, even at low energies, which was not the case for its 
5,3-counterpart. For this reason, the pyrolytic stability of both compounds was assessed to 
account for thermolytic ‘metabolite’ formation during smoking. However, no pronounced 
difference in the pyrolytic stability between the two regioisomers could be observed. Three 
and four ‘metabolites’ were detected in the smoke condensates, respectively (Supplemental 
Figure S3). In both cases the main pyrolytic degradation product was the primary amide 
cleavage product (~ 3 %), which was identified as one of the metabolites as well. Similar 
reactions were observed for other valinamide containing synthetic cannabinoids like e.g. AB-
CHMINACA[12]. Although uptake of these metabolites via smoke might most probably not 
contribute much to the overall in vivo metabolite findings they could lead to problems when 
interpreting hair analysis results, as ‘metabolite’ findings of chemically labile compounds 
caused by smoke condensed on hair could be misinterpreted as a proof of consumption. 
 
In summary, metabolic patterns of both AB-CHMFUPPYCA isomers were qualitatively 
similar. Oxidation of the cyclohexylmethyl side chain was the dominant metabolic reaction. 
The presented data suggest monohydroxylated metabolites (Figures 2 and 3) as suitable 
targets for urine analysis. For differentiation of the two isomers the characteristic fragment 
ion m/z 260 of 3,5-AB-CHMFUPPYCA could be useful. 5,3-AB-CHMFUPPYCA was more 
efficiently transformed by human liver microsomes when compared to the 3,5-isomer. 
Moreover, cannabinoid receptor binding and activity may differ between the isomers. 
Comparing the structures to the known CB1 receptor antagonist Rimonabant, the similarity to 
the 5,3-isomer could lead to antagonistic activity, making it unattractive as a cannabis 
alternative. Regarding the thermolytic stability of the isomers, no remarkable difference was 
observed. Pyrolytic cleavage of the primary amide bond occurred under smoking conditions 
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leading to approximately 3 % conversion to artefactual ‘metabolites’. This could bias in vivo 
metabolic profiles after smoking and would have to be considered for interpretation of 
metabolite findings in hair analysis as well. 
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Table 1. Identified metabolites of 3,5-AB-CHMFUPPYCA after 1h incubation with pooled human liver microsomes (pHLM) in the order of their retention time (RT). All 
determinations were performed in triplicate. For the ranking the mean area ratios between the metabolite and the most abundant metabolite (A08) was used and relative standard 
deviations (RSD) are given. The four most abundant metabolites are highlighted in bold type. Biotansformation sites: Cyclohexylmethyl (CHM) or valinamide (VA) moiety. 
ID Biotransformation Site RT [min] Formula m/z [Da] Major fragment ions [Da] Area ratio RSD Rank 
--- 3,5-AB-CHMFUPPYCA --- 18.3 C22H30FN4O2 401 189, 260, 356 --- --- --- 
A01 Dihydroxylation CHM + VA 6.5 C22H30FN4O4 433 189, 258, 276, 370 3.0% 8.4% 12 
A02 Dihydroxylation CHM 7.2 C22H30FN4O4 433 189, 260, 415 2.2% 16.7% 16 
A03 Dihydroxylation CHM + VA 7.3 C22H30FN4O4 433 189, 258, 276, 415 3.3% 10.0% 11 
A04 Dihydroxylation CHM + VA 7.7 C22H30FN4O4 433 189, 258, 276, 283 4.2% 3.9% 10 
A05 Hydroxylation + ketone CHM 7.8 C22H28FN4O4 431 189, 260, 327, 386, 415 1.1% 9.2% 21 
A06 Dihydroxylation CHM 8.2 C22H30FN4O4 433 189, 260, 415 1.3% 6.9% 18 
A07 Dihydroxylation CHM 8.4 C22H30FN4O4 433 189, 260, 352, 415 1.1% 4.1% 20 
A08 Hydroxylation CHM 9.0 C22H30FN4O3 417 189, 260, 372 100.0% 0.0% 1 
A09 Hydroxylation CHM 9.6 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 39.9% 4.0% 4 
A10 Hydroxylation CHM 9.8 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 71.5% 0.3% 3 
A11 Hydroxylation CHM 10.2 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 82.8% 2.4% 2 
A12 Ketone CHM 10.4 C22H28FN4O3 415 189, 299, 370, 398 6.6% 8.9% 8 
A13 Ketone CHM 10.9 C22H28FN4O3 415 189, 260, 370, 398 32.2% 12.6% 6 
A14 Hydroxylation CHM 11.9 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 1.2% 5.5% 19 
A15 Hydroxylation + hydrolysis CHM + VA 12.1 C22H29FN3O4 418 189, 260, 400 0.3% 11.1% 22 
A16 Hydroxylation CHM 13.1 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 2.7% 5.3% 13 
A17 Dihydroxylation VA 13.3 C22H30FN4O4 433 189, 246, 274, 302, 388, 416 1.6% 5.6% 17 
A18 Hydroxylation CHM 13.8 C22H30FN4O3 417 189, 260, 283, 354, 382, 399 5.7% 11.8% 9 
A19 Hydroxylation VA 15.1 C22H30FN4O3 417 189, 258, 276, 372 39.3% 16.4% 5 
A20 Dehydrogenation CHM 17.0 C22H28FN4O2 399 189, 260, 354 2.5% 19.8% 14 
A21 Dehydrogenation VA 18.1 C22H28FN4O2 399 189, 258, 354 11.4% 16.8% 7 
A22 Hydrolysis VA 20.5 C22H29FN3O3 402 189, 260, 385 2.3% 4.1% 15 
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Table 2. Identified metabolites of 5,3-AB-CHMFUPPYCA after 1h incubation with pooled human liver microsomes (pHLM) in the order of their retention time (RT). All 
determinations were performed in triplicate. For the ranking the mean area ratios between the metabolite and the most abundant metabolite (B06) was used and relative standard 
deviations (RSD) are given. The four most abundant metabolites are highlighted in bold type. Biotansformation sites: Cyclohexylmethyl (CHM) or valinamide (VA) moiety. 
ID Type Site RT [min] Formula m/z [Da] Major fragment ions [Da] Area ratio RSD Rank 
--- 5,3-AB-CHMFUPPYCA --- 17.3 C22H30FN4O2 401 189, 285, 356, 384 --- --- --- 
B01 Dihydroxylation CHM + VA 6 C22H30FN4O4 433 189, 301, 370, 388, 416 11.0% 13.7% 6 
B02 Hydroxylation + ketone CHM 6.2 C22H28FN4O4 431 189, 315, 327, 386, 414 0.7% 23.5% 21 
B03 Hydroxylation + ketone CHM + VA 7 C22H28FN4O4 431 189, 299, 368, 386, 396, 414 1.4% 25.9% 16 
B04 Dihydroxylation CHM + VA 7.4 C22H30FN4O4 433 189, 301, 370, 388, 416 2.4% 10.7% 13 
B05 Hydroxylation + dehydrogenation CHM + VA 7.8 C22H28FN4O3 415 189, 301, 370, 398 1.2% 18.6% 19 
B06 Hydroxylation CHM 8 C22H30FN4O3 417 189, 301, 354, 372, 400 100.0% 0.0% 1 
B07 Hydroxylation CHM 8.2 C22H30FN4O3 417 189, 283, 301, 354, 372, 400 9.4% 2.5% 8 
B08 Hydroxylation CHM 8.5 C22H30FN4O3 417 189, 283, 301, 354, 372, 400 19.4% 1.8% 4 
B09 Hydroxylation CHM 8.6 C22H30FN4O3 417 189, 283, 301, 354, 372, 400 13.3% 5.5% 5 
B10 Ketone CHM 8.9 C22H28FN4O3 415 189, 299, 370, 398 2.8% 5.8% 12 
B11 Hydroxylation CHM 9.3 C22H30FN4O3 417 189, 301, 354, 372, 400 4.6% 3.8% 10 
B12 Ketone CHM 9.3 C22H28FN4O3 415 189, 299, 370, 398 19.8% 23.7% 3 
B13 Hydroxylation CHM 9.7 C22H30FN4O3 417 189, 301, 354, 372, 400 27.4% 3.6% 2 
B14 Hydroxylation + hydrolysis CHM 9.9 C22H29FN3O4 418 189, 283, 301, 372, 400 2.1% 27.2% 14 
B15 Hydroxylation CHM 10.6 C22H30FN4O3 417 189, 301, 372, 400 1.2% 3.6% 18 
B16 Hydroxylation CHM 11.8 C22H30FN4O3 417 189, 260, 301, 354, 372, 400 1.3% 5.9% 17 
B17 Dihydroxylation VA 12.9 C22H30FN4O4 433 189, 285, 416 0.8% 19.1% 20 
B18 Hydroxylation VA 13.1 C22H30FN4O3 417 189, 285, 400 5.6% 10.1% 9 
B19 Hydroxylation VA 14.3 C22H30FN4O3 417 189, 285, 354, 372, 400 10.9% 6.9% 7 
B20 Hydrolysis (secondary amide) VA 15.5 C17H20FN2O2 303 189, 285 0.3% 12.7% 23 
B21 Dehydrogenation CHM 15.7 C22H28FN4O2 399 189, 283, 354 0.5% 15.1% 22 
B22 Dehydrogenation VA 17.1 C22H28FN4O2 399 189, 285, 354, 382 1.5% 21.6% 15 
B23 Hydrolysis (primary amide) CHM 19.6 C22H29FN3O3 402 189, 285, 356 3.4% 1.2% 11 
 
 11 
Figure 1. Molecular structures of the novel pyrazole compounds in comparison to JHW-307 
and Rimonabant. 
 
Figure 2. Enhanced product ion scans recorded using a collision energy of 35 V with a spread 
of 15 V of the four most abundant metabolites (A08, A09, A10, A11) identified after 1h 
incubation of 3,5-AB-CHMFUPPYCA with pooled human liver microsomes and proposed 
fragmentation. 
 
Figure 3. Enhanced product ion scans recorded using a collision energy of 35 V with a spread 
of 15 V of the four most abundant metabolites (B06, B08, B12, B13) identified after 1h 
incubation of 5,3-AB-CHMFUPPYCA with pooled human liver microsomes and proposed 
fragmentation. 
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